AFX Carl Zeiss Meditec AG

DGAP-News: Carl Zeiss Meditec AG: Postponement of the Annual General Meeting 2020 in the course of tightening up the regulations for public events

DGAP-News: Carl Zeiss Meditec AG / Key word(s): AGM/EGM
Carl Zeiss Meditec AG: Postponement of the Annual General Meeting 2020 in the course of tightening up the regulations for public events

17.03.2020 / 10:38
The issuer is solely responsible for the content of this announcement.

Carl Zeiss Meditec AG: Postponement of the Annual General Meeting 2020 in the course of tightening up the regulations for public events
 
 

JENA, 17 March 2020

On the basis of the decree of the President of the State Administration Office of Thuringia (Landesverwaltungsamt Thüringen) of 14 March 2020, according to which "events and meetings of people with 50 or more persons must be prohibited from now until further notice", the Management Board of Carl Zeiss Meditec AG has decided to postpone the Annual General Meeting, which was scheduled for Tuesday, 24 March 2020 (published in the Federal Gazette (Bundesanzeiger) of 11 February 2020); it will therefore not take place. A new date will be announced in time.

 

Contact for investors and press

Sebastian Frericks
Director Investor Relations, Carl Zeiss Meditec AG
Tel. 03641 220-116
E-Mail:


17.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail:
Internet: /meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 999125

 
End of News DGAP News Service

999125  17.03.2020 

fncls.ssp?fn=show_t_gif&application_id=999125&application_name=news&site_id=research_pool
EN
17/03/2020

Underlying

AFXCarl Zeiss Meditec AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Carl Zeiss Meditec AG

Thomas J. Schiessle
  • Thomas J. Schiessle
EUR 290.00
AFX Carl Zeiss Medi...

Q1 weak as expected - destocking in China by mid-24 - 24 guidance conf...

The weak start to the year shows: The economic and inventory cycle turning point - in the SBU "OPT" - has not yet been reached. Investors are waiting for a change of trend in consumer confidence (CCI), particularly in China. The Q1/24 (€ 475.0m (nom. +1.0% in CC: +3.3%; Q4/23: +1.7% YoY), showed an increase in device sales compared to the previous year. By contrast, the very profitable sale of consumables suffered from the ongoing destocking in China. Meanwhile, AFX is strengthening its position...

AFX CARL ZEISS MEDITEC AG
02/12/24 February 12, 2024 4 EN
Thomas J. Schiessle
  • Thomas J. Schiessle
EUR 290.00
AFX Carl Zeiss Medi...

Q1 wie erwartet schwach – Lagerabbau in China bis Mitte 24 - 24er Guid...

Der schwache Jahresstart zeigt: Noch ist der konjunkturelle und lagerzyklische Wendepunkt – im SBU „OPT“ - nicht erreicht. Die Investoren warten auf einen Trendwechsel beim Consumer Confidence (CCI) insbesondere in China. Das Q1/24 (€ 475,0 Mio. (nom. +1,0 % in CC: +3,3 %; Q4/23: +1,7 %), zeigte zum Vorjahr eine Steigerung der Geräteverkäufe. Der sehr profitable Verbrauchsmaterialienverkauf dagegen litt unter dem anhaltenden Lagerabbau in China. Unterdessen stärkt sich AFX durch einen gewichtige...

AFX CARL ZEISS MEDITEC AG
02/12/24 February 12, 2024 5 DE
Baptiste Lebacq ... (+6)
  • Baptiste Lebacq
  • Louis Boujard
  • CFA
  • Marc Lavaud
  • Philippe Ourpatian
  • Thomas Zlowodzki
AKRBF AKER BP ASA
PUB Publicis Groupe... ... (+13)

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/09/2024

Falling inflation and weaker growth (in Europe) and – paradoxically – higher interest rates are driving an upturn in M&A in Europe. The sectors that are expected to be the most active are: healthcare, technology, industry, telecoms and utilities/renewables. We present the M&A outlook for all sectors of activity and identify 80 potentially active companies (predators, targets, buyers or sellers of assets). - ...

AKRBF AKER BP ASA
PUB PUBLICIS GROUPE SA
UBI UBISOFT ENTERTAINMENT SA
DG VINCI SA
DB1 DEUTSCHE BOERSE AG
AFX CARL ZEISS MEDITEC AG
GLE SOCIETE GENERALE S.A. CLASS A
CPG COMPASS GROUP PLC
OR L'OREAL SA
KER KERING SA
VER VERBUND AG CLASS A
COLO B COLOPLAST A/S CLASS B
SIE SIEMENS AG
02/09/24 February 9, 2024 1 EN
Baptiste Lebacq ... (+6)
  • Baptiste Lebacq
  • Louis Boujard
  • CFA
  • Marc Lavaud
  • Philippe Ourpatian
  • Thomas Zlowodzki
AKRBF AKER BP ASA
PUB Publicis Groupe... ... (+13)

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 09/02/2024

La baisse de l’inflation et de la croissance (en Europe) et – paradoxalement – des taux d’intérêt plus hauts incitent à une reprise du M&A en Europe. Les secteurs qui devraient être les plus actifs sont : la Santé, la Technologie, l’Industrie, les Télécoms et les Utilities/Renouvelables. Nous présentons les perspectives M&A pour l’ensemble des secteurs d’activité et identifions 80 sociétés potentiellement actives (prédatrices, cibles, acquéreuses ou cédantes d’actifs). - ...

AKRBF AKER BP ASA
PUB PUBLICIS GROUPE SA
UBI UBISOFT ENTERTAINMENT SA
DG VINCI SA
DB1 DEUTSCHE BOERSE AG
AFX CARL ZEISS MEDITEC AG
GLE SOCIETE GENERALE S.A. CLASS A
CPG COMPASS GROUP PLC
OR L'OREAL SA
KER KERING SA
VER VERBUND AG CLASS A
COLO B COLOPLAST A/S CLASS B
SIE SIEMENS AG
02/09/24 February 9, 2024 1 FR
Oliver Metzger
  • Oliver Metzger
AFX Carl Zeiss Medi...

Carl Zeiss Meditec : Q1 review – Bottom line beat driven by Microsurge...

>Q1 review – Beat on the bottom line - Q1 2024 revenues € 475.0m (+1.0% y-o-y) were driven by cc growth of c. 3.3% and a forex headwind of 230bp, or 0%/+2% vs ODDO BHF/consensus. EBIT of € 43.5m (-27.9% y-o-y, margin 9.2%) was 12%/13% ahead of expectations. Adj. EBIT reached € 46.0m (-27.1% y-o-y, margin 9.7%) and was 14%/18% vs consensus. EPS of € 0.42 compares to expectations of € 0.29 and € 0.34 for the consensus driven by a better financial result.Oph...

AFX CARL ZEISS MEDITEC AG
02/09/24 February 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch